- McKesson’s fourth-quarter adjusted EPS was $10.12, surpassing estimates of $9.75 and significantly higher than last year’s $6.18.
- Total revenue reached $90.82 billion, a 19% increase from the previous year, although below the estimate of $94.02 billion.
- US pharmaceutical revenue was $83.17 billion, marking a 21% rise year-over-year, but short of the projected $85.87 billion.
- International revenue experienced a decline of 2.5% year-over-year, totaling $3.46 billion, compared to the estimate of $3.64 billion.
- Revenue from medical-surgical solutions was $2.85 billion, a slight 0.6% increase year-over-year, and above the estimate of $2.8 billion.
- Prescription technology solutions revenue increased by 13% year-over-year, amounting to $1.34 billion, close to the expected $1.38 billion.
- Adjusted operating income amounted to $1.56 billion, a 24% increase from the previous year, exceeding the estimate of $1.52 billion.
- The company received 14 buy recommendations, 3 hold, and 1 sell from analysts.
Mckesson Corp on Smartkarma
Analyst coverage of McKesson Corp on Smartkarma by Baptista Research showcases a positive outlook for the company. In the report titled “Is McKesson Wall Street’s Safe Haven? How This Drug Giant Can Thrive In Uncertain Times,” the analysts highlight McKesson’s resilience in the face of global trade uncertainty and economic risks. They emphasize the company’s diversified business model and essential role in healthcare delivery as factors that could shield it from market headwinds.
Additionally, in the report “McKesson Corporation: Growth in Prescription Technology Solutions (RxTS) to Solidify Its Competitive Advantage,” Baptista Research points out McKesson’s strong financial performance in the third quarter of fiscal 2025. The company’s revenue increased by 18%, reaching $95.3 billion, with significant growth in adjusted operating profit. The analysts underscore McKesson’s operational strength and competitive advantage, particularly in the U.S. Pharmaceutical and Prescription Technology Solutions segments.
A look at Mckesson Corp Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 0 | |
| Dividend | 2 | |
| Growth | 4 | |
| Resilience | 4 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
McKesson Corp, a leading distributor of pharmaceuticals and healthcare products in North America, is poised for a promising long-term outlook based on its Smartkarma Smart Scores. With strong scores in Growth, Resilience, and Momentum, the company demonstrates robust potential for expanding its market presence, maintaining stability during challenging times, and sustaining positive stock performance.
While McKesson Corp’s Value score may be lower, its emphasis on growth, resilience, and momentum positions it well for future success in the healthcare industry. Investors looking for a company with solid growth prospects, resilience in uncertain markets, and strong stock momentum may find McKesson Corp an attractive long-term investment opportunity.
**Summary**:
McKesson Corporation distributes pharmaceuticals, medical-surgical supplies, and healthcare products in North America. Additionally, the company develops software for healthcare data integration, and offers analytic, care management, and patient solutions for payers.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
